Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Careers and Recruitment
  • Published:

Compensation inflation remains consistent at private life science companies

Nature Biotechnology volume 34, pages 667–670 (2016)Cite this article

Subjects

Non-founder total target cash compensation increased 3.3% at private life science companies in 2015.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2: Screenshot of a sample CompStudy base salary histogram from a 2015 survey.
Figure 3

References

  1. Rychlik, B. Nat. Biotechnol. 33, 313–316 (2015). Medline

    Article  CAS  Google Scholar 

  2. Rychlik, B. Nat. Biotechnol. 32, 393–395 (2014). Medline

    Article  CAS  Google Scholar 

  3. Wasserman, N. The Founder's Dilemmas: Anticipating and Avoiding the Pitfalls That Can Sink a Startup (Princeton Univ. Press, 2012).

    Book  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bruce Rychlik is at Park Square Executive Search LLC, Boston, Massachusetts, USA.,

    Bruce Rychlik

Authors
  1. Bruce Rychlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bruce Rychlik.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rychlik, B. Compensation inflation remains consistent at private life science companies. Nat Biotechnol 34, 667–670 (2016). https://doi.org/10.1038/nbt.3604

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3604

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research